Breaking Finance News

Zacks Investment Research downgraded Hill-Rom Holdings, Inc. (NYSE:HRC) to Hold in a report released today.

Yesterday Hill-Rom Holdings, Inc. (NYSE:HRC) traded 0.57% higher at $61.87. The company’s 50-day moving average is $59.51 and its 200-day moving average is $53.24. The last stock close price is up 16.20% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. Trade Volume was up over the average, with 801,103 shares of HRC changing hands over the typical 512,868

Zacks Investment Research has downgraded Hill-Rom Holdings, Inc. (NYSE:HRC) to Hold in a report released on Wednesday October 05, 2016.

Previously on Wednesday September 21, 2016, Zacks Investment Research reported about Hill-Rom Holdings, Inc. (NYSE:HRC) raised the target price from $0.00 to $66.00. At the time, this indicated a possible upside of 0.11%.

Recent Performance Chart

Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. has PE ratio of 63.71 with a one year low of $42.99 and a one year high of $62.43 and has a market capitalization of $0.

General Company Details For Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn. The North America segments sells and rents its support and near-patient technologies and services, as well as its clinical workflow solutions in the United States and Canada. The Surgical and Respiratory Care segment sells and rents its surgical and respiratory care products across the globe. Its International segment sells and rents similar products as the Company's North America segment in regions outside of the United States and Canada. Its Welch Allyn segment sells medical diagnostic equipment and a portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases across the globe.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *